Biomarkers for the diagnosis and treatment of pancreatic cancer

摘要

Compositions and methods for use in methods and kits for the detection of an increased risk of pancreatic cancer are provided. Cyst fluid samples isolated from patients that are positive for at least three of the following markers, mucin 1, mucin 2, mucin 5AC, mucin 5B, mucin 6, CEA CAM 1, CEACAM 5, CEACAM 6, CEACAM 7, CEACAM 8, S100-A6, S100-A8, S100-A9 and S100-A11 indicate that such patients are at greater risk for development of pancreatic cancer when compared to cyst fluid samples isolated from patients lacking these markers.

主权项

1. A method of diagnosing an increased risk for the development of pancreatic cancer in a human test subject, said method comprising:
a) obtaining a pancreatic cyst fluid specimen from a human test subject; b) analyzing said fluid specimen for the presence of at least three biomarkers for pancreatic carcinoma identifiable in said cyst fluid sample via mass spectroscopy, said presence being indicative of an increased risk for pancreatic cancer, said biomarkers being selected from the group consisting of mucin 1, mucin 2, mucin 5AC, mucin 5B, mucin 6, CEA CAM 1, CEACAM 5, CEACAM 6, CEACAM 7, CEACAM 8, S100-A6, S100-A8, S100-A9 and S100-A11, and c) diagnosing said patient as being at increased risk based on the presence of said markers in said sample.